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An abnormally expanded GGGGCC repeat in C9ORF72 is the most frequent causal
mutation associated with amyotrophic lateral sclerosis (ALS)/frontotemporal lobar
degeneration (FTLD). Both gain-of-function (gf ) and loss-of-function (lf ) mechanisms
have been involved in C9ORF72 related ALS/FTLD. The gf mechanism of C9ORF72
has been studied in various animal models but not in C. elegans. In the present study,
we described mutant C9ORF72 modeling in C. elegans and report the finding of two
suppressor genes. We made transgenes containing 9 or 29 repeats of GGGGCC in
C9ORF72, driven by either the hsp-16 promoters or the unc-119 promoter. Transgenic
worms were made to carry such transgenes. Phenotypic analysis of those animals
revealed that Phsp−16::(G4C2)29::GFP transgenic animals (EAB 135) displayed severe
paralysis by the second day of adulthood, followed by lethality, which phenotypes were
less severe in Phsp−16::(G4C2)9::GFP transgenic animals (EAB242), and absent in control
strains expressing empty vectors. Suppressor genes of this locomotor phenotype were
pursued by introducing mutations with ethyl methanesulfonate in EAB135, screening
mutant strains that moved faster than EAB135 by a food-ring assay, identifying mutations
by whole-genome sequencing and testing the underlying mechanism of the suppressor
genes either by employing RNA interference studies or C. elegans genetics. Three
mutant strains, EAB164, EAB165 and EAB167, were identified. Eight suppressor genes
carrying nonsense/canonical splicing site mutations were confirmed, among which a
nonsense mutation of F57A10.2/VAMP was found in all three mutant strains, and
a nonsense mutation of acp-4/ACP2 was only found in EAB164. Knock down/out
of those two genes in EAB135 animals by feeding RNAi/introducing a known acp-4
null allele phenocopied the suppression of the C9ORF72 variant related movement
defect in the mutant strains. Translational conformation in a mammalian system is
required, but our worm data suggest that altering acp-4/ACP2 encoding lysosomal acid
phosphatasemay provide a potential therapeutic method of reducing acp-4/ACP2 levels,
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as opposed or complementary to directly reducing C9ORF72, to relieve C9ORF72-ALS
phenotypes. It also suggests that the C9ORF72-ALS/FTLD may share a
pathophysiologic mechanism with vesicle-associated membrane protein-associated
protein B, a homolog of F57A10.2/VAMP, which is a proven ALS8 gene.
Keywords: Caenorhabditis elegans, C9ORF72, ALS-FTLD, VAPB, ACP2, amyotrophic lateral sclerosis
INTRODUCTION
Abnormal expansion of a GGGGCC hexanucleotide (G4C2)
repeat in a noncoding region of C9ORF72 is the most
commonly identified genetic variant associated with both familial
amyotrophic lateral sclerosis (ALS) and familial frontotemporal
dementia (FTD) (DeJesus-Hernandez et al., 2011; Renton
et al., 2011). Various genetic models, including C9ORF72
knock-outs (KO) in M. musculus and zebrafish, have been
constructed based on this finding (Ciura et al., 2013; O’Rourke
et al., 2016). C9ORF72 gain-of-function (gf) models, testing
Repeat-Associated Non-ATG Translation (RANT) of G4C2,
have also been developed in S. cerevisiae, human iPSC-
derived neuronal cells and Drosophila, which have identified
nucleocytoplasmic transportation pathway anomalies as part of
the pathogenetic mechanism of C9ORF72 associated ALS/FTLD
(C9-ALS) (Mizielinska et al., 2014; Wen et al., 2014; Freibaum
et al., 2015; Jovicˇic´ et al., 2015).
C. elegans offers a range of unique experimental advantages,
many of which are not available in other organisms. Importantly,
C. elegans has a fully developed nervous system and has most
of the neurotransmitters that have been implicated in the
pathogenesis of human neurologic illnesses, including the two
major mammalian neurotransmitters, GABA and glutamate, as
well as dopamine, serotonin, and acetylcholine neurotransmitter
systems. Many gene systems of interest in neurology are
conserved between C. elegans and humans, including those
for neurotransmitter receptors, second messenger systems,
ion channels, synaptic proteins, and enzymes required for
neurotransmitter synthesis (Shaye and Greenwald, 2011). For
example,∼83% of theC. elegans proteome has homologous genes
in humans (Lai et al., 2000). In past studies, our group has shown
that reverse genetic approaches in C. elegans identify important
signal transduction pathways through which neurologic disease
associated genes act (Buttner et al., 2007; Wang et al., 2016) and
that pharmacogenomic studies in C. elegans identify novel drug
targets relevant to neuropsychiatric disease (Karmacharya et al.,
2009; Saur et al., 2013; Haeusler et al., 2014). Moreover, C. elegans
reverse genetic experiments have defined novel mechanisms
of action of FTD genes, specifically including the role of the
programmed cell death pathway in the action of progranulin
gene mutations (Kao et al., 2011). In C. elegans, a C9ORF72
homolog KO model was used to study the loss-of-function (lf )
mechanism of C9ORF72 (Therrien et al., 2013). We also reported
the observation of developmental and locomotive phenotypes
based on C9ORD72/alfa-1 lf approaches (Wang and Buttner,
2013), but no such model has been described to test the
toxic effects of the G4C2 disease-related fragment, thought to
be an underlying pathophysiologic mechanism of ALS. Given
that C9ORF72-linked neurodegeneration involves multiple gf
mechanisms, including disrupted RNA homeostasis, toxic RNA
foci and protein aggregates due to RANT (Ciura et al., 2013;
Mori et al., 2013), there is potential value in defining the
genetic pathways through which C9ORF72 mutations produce
phenotypic abnormalities in a gf C. elegans model. Here we
report such C9ORF72 gf modeling in C. elegans and the
subsequent findings of molecular components related to its ALS-
like phenotypes. To the best of our knowledge, this is the first
report of C. elegans C9ORF72 gf modeling of AS/FTLD.
MATERIALS AND METHODS
Nematode Culture and Strains
The nematodes were cultured under standard culture conditions
in a 20◦C incubator (Brenner, 1974). C. elegans Bristol strain N2
was used as a control. Other strains used/made are presented
in Supplementary Table 1. Newly generated strains were
backcrossed at least 4 times to the N2 strain. Nonsense and
canonical splicing site mutations detected by next generation
sequencing were confirmed by DNA Sanger sequencing at
the Dana-Farber/Harvard Cancer Center DNA Resource
Core.
Plasmid Constructions
To produce Punc-119::(G4C2)n ::GFP and Phsp-
16::(G4C2)n::GFP C. elegans expression constructs, we first
amplified human C9ORF72 genomic fragment containing the
G4C2 repeat: 5′caaggagggaaacaaccgcagcctgtagcaagctctggaactca
ggagtcgcgcgcta(ggggcc)nggggcgtggtcggggcgggcccgggggcgggccc
ggggcggggctgcggttgcggtgcctgc3′. Primers for this reaction were
available on request. Healthy human genomic DNA was used
as PCR template. The PCR products were subcloned into the
TOPO R© TACloning vector (Invitrogen, CAUSA) to get (G4C2)n
TOPO constructs, and then sequenced to determine the repeat
number of G4C2. The maximal number we could achieve by this
method was 29 due to the high GC% of the repeat sequence. The
reference repeat number was determined as 9. (G4C2)n TOPO
constructs were digested with NotI and KpnI restriction enzymes
to generate the fragment containing (G4C2)n, which was ligated
with Fire Lab vectors L3787 and L3788 (Addgene) and processed
with EagI and KpnI restriction enzymes. By this method,
we generated Phsp-16::(G4C2)n::GFP C. elegans expression
constructs (n= 29 or 9). The Punc119::GFP C. elegans expression
construct, based on ppd95.75, was a gift from Prof. Craig
Hunter at the Harvard Medical School. We inserted (G4C2)n
fragments from (G4C2)n TOPO constructs into Punc119::GFP
constructs using XbaI and KpnI restriction enzymes to generate
Phsp-16::(G4C2)n::GFP C. elegans expression constructs (n = 29
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 November 2016 | Volume 9 | Article 113
Wang et al. Suppressors of an ALS Phenotype
or 9). All plasmid constructions were confirmed by sequencing
at the Dana-Farber/Harvard Cancer Center DNA Resource Core.
Transgenic Animals
Extrachromosomal transgenic lines were produced by injecting
Punc-119::(G4C2)n::GFPand Phsp-16::(G4C2)n::GFPconstructs at
40∼50 ng/µl into young adult N2 gonads (Mello et al., 1991).
L3787, L3788 and Punc119::GFP constructs were also injected
at 40∼50 ng/µl into N2 gonads to generate the control worm
strains. Pmyo-3::DsRed2 (pHC183) at ∼50 ng/µl was used
as a co-injection marker(Saur et al., 2013). 2–3 independent
extachromasomal lines per construct were integrated into the
germline by a standard gamma radiation method described by
Prof. Michael Koelle at Yale University. The gamma radiation
experiments were performed at Prof. Mark Alkema’s laboratory
at UMASS Medical School. Two independent lines per construct
were outcrossed to N2 strain at least 4 times. Only experimental
results that were consistent across both lines per construct were
reported. A list of the transgenic animals we made appears in
Supplementary Table 1. To obtain imaging, worms were picked
onto a slide with an agarose pad containing 20 mM sodium azide,
and observed under a Zeiss Axio2 microscope (Leica).
Screening for Suppressors of the
Movement Defect of EAB135
[Phsp-16::(G4C2)29::GFP]
We selected EAB135 animals and took advantage of their
movement defects to perform genetic suppressor screens. We
adopted the principle of the food-ring assay (Zengel and Epstein,
1980). Animals of L4 progeny (P0) were harvested and treated
with ethyl methanesulfonate (EMS), after rinsing off EMS with
M9 buffer, those animals were cultured at 20◦C for 36–48 h
until they reached the second day of adulthood, then they
were bleached to obtain synchronized L1s (F1) after overnight
incubation. F1s were cultured to the first day of adulthood and
were bleached to obtain synchronized L1s (F2). NGM plates
of 100 cm diameter were seeded with OP50 on the edge of
the surface and were incubated at 37◦C overnight to form a
bacterium ring 1 day prior to the addition of F2s grown to Day
1 adults. Those animals were rinsed multiple times with M9
buffer until they were free of bacteria, and were placed in the
center of the plates. Animals reaching the ring faster than the
original EAB135 animals were picked as suppressor candidates.
This procedure usually generated about 3–5 candidates for each
round of screens of∼16,000 haploid genomes, and we performed
five rounds of screens.
Whole-Genome Sequencing and Data
Analysis
Synchronized L1 animals were seeded on 10 NMG plates (8.5
cm diameter), grown until they were gravid adults, and then
washed off with M9 buffer and harvested in several 50 ml
Conical tubes. After rinsing with M9 2–3 times, the animals
were left on a NUTATOR mixer for 2 h to eliminate food
in the gut, then were washed again with M9 2–3 times.
The supernatant was removed after centrifugation at 1500 g
for 3 min. A total 500 µl worm pellet was achieved by
such method. For DNA extraction, we followed the protocol
of Gentra Puregene Kit (Qiagen). The concentration of the
final DNA preparation was determined by the Qubit assay
(Invitrogen) at the Bauer Core Facility, Harvard University. 1
µg DNA was used for further sequencing library construction
and next generation sequencing at BGI Americas (Cambridge
MA USA). In brief, the sequencing libraries were made per
the TruSeq R©DNA PCR-free sample preparation kit (Illumina),
and next generation sequencing was performed on an Illumina
HiSeq seq platform. The sequencing results were analyzed
both at BGI Americas Inc. and at the High-performance
Computation Facility of the Partners Healthcare System. In
brief, the sequencing reads were first mapped to the reference
genome, such as WS220, with Bowtie-0.12.7, the variants were
called with Samtools, and they were visualized by the Integrative
Genomics Viewer developed by the Broad Institute. Nonsense
mutations producing nonsense-mediated mRNA decay (NMD)
and canonical splicing sitemutations were noticed and confirmed
by Sanger sequencing.
Feeding RNAi
We employed gene-specific RNAi cultures from Ahringer’s RNAi
feeding library (Geneservice Ltd) to carry out RNAi experiments,
using the Ahringer’s feeding RNAi protocol (Kamath, 2000).
RNAi exposed cultures were grown overnight at 37◦C in 100 ml
of LB with 100 mg/ml of ampicillin, then poured on NGM plates
containing 25 µg/ml carbenicillin and 1mM IPTG. The cultures
were dried and induced overnight in a 37◦C incubator. Animals
cultured onOP50 were collected and bleached to obtain embryos,
and were starved in M9 buffer to obtain synchronized L1s. Those
L1 stage animals were then cultured on NGM plates seeded with
HT115 to achieve the desired stage for RNAi. We used dpy-6
RNAi as the positive control.
Developmental/Behavioral Assays
To obtain the developmental data, we bleached the well-
grown adult animals using standard bleach solution to obtain
synchronized L1s, 25∼50 of which were then placed on seeded
NGM plates. Afterwards, the plates were observed and the
developmental status was recorded every 24 h for 5–10 days. At
least three independent experiments were performed for each
study and a typical result was shown. For thrashing assays, we
minimized contamination with E. coli by rinsing and soaking
animals in two Petri dishes filled with M9 buffer. Animals were
then transferred to NGM plates (35 mm diameter) with 1 ml of
M9 buffer and allowed to accommodate for 1 min. We counted
the number of thrashes for 20 s under the dissecting microscope.
Only continuous movements were scored, and at least 25 animals
were tested for each condition.
Statistical Analysis
Data were expressed as means ± standard deviations. Statistical
comparisons were all performed using unpaired, two-tailed
Student’s t-tests.
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RESULTS
Phenotypic Characterization of
(G4C2)9/29::GFP Strains
Transgenes were driven by either the hsp-16 promoter, for
conditional global expression, or by the unc-119 promoter,
for pan-neuronal expression. C9ORF72 genomic fragments
of (G4C2)9/29 in those transgenes were inserted between the
transcriptional start site and the translational start site, thus
mimicking their role as part of 5′-UTR in human C9ORF72
(Figure 1A). Integrated transgenic animals were obtained. At
25◦C, Phsp−16::(G4C2)29::GFP transgenic animals (strain EAB
135) displayed severe paralysis by the second day of adulthood,
followed by lethality. These phenotypes were not observed in
wild-type animals and animals expressing the empty vector
(strain EAB141), and were less severe in animals carrying the
Phsp−16::(G4C2)9::GFP transgene (strain EAB242). For example,
∼85% of EAB135 animals were dead by day 10 of adulthood
when cultured at 25◦C, compared to ∼18% for N2 or EAB242
(Figures 1D, 2). When culturing at 20◦C without heat-shocking,
EAB135 animals still showed a number of age-dependent
phenotypes, including increased lethality, movement defects,
reduced brood size and impaired life span (Figures 1B–E). In the
swimming assay, EAB135 animals had 45 and 4.5 thrashes/20 s
at Day 1 of adulthood and at Day 10 of adulthood, respectively;
both were significantly compromised relative to 71 and 60.7
thrashes/20 s in EAB141 animals carrying the empty vector (P <
0.05 and < 0.001, respectively. See Figure 1D). EAB 242 animals
had similar but less severe movement deficits and reduced
life span phenotypes, compared to the normal behaviors and
life span of strain EAB141. At Day 10 of adulthood, EAB242
animals had 30.5 thrashes/20 s, which fell in the middle of
EAB141 control animals and EAB135 animals. EAB242 animals
also had a life span of about 24 days between 17 days of
EAB135 and 28 days of EAB141. To our surprise, both EAB243
and EAB135 animals did not show significant enhancement
of GFP when exposed to various heat shock protocols, which
response was intact in those strains expressing the empty vector
(Figure 3A). We confirmed the presence of the transgenes in
EAB135 and EAB242 animals by PCR and sequencing. Given the
repeat number dependent phenotypes mentioned above and that
the heat shock response of hsp-16.2/41 promoters requires the
nuclearpore transportation (NPT) pathway(Rohner et al., 2013),
which is impaired in C9ORF72-ALS/FTLD (Wen et al., 2014;
Freibaum et al., 2015; Jovicˇic´ et al., 2015), it appears possible
that this loss-of-heat shock response is due to G4C2 repeats, as
well. If that is the case, interrupting the NPT pathway would
likely result in a more devastating effect to wide type animals,
rather than to EAB135/EAB164 animals, in which that pathway
has already been impaired. Indeed, when we reduced the levels
of NPP-10 (ortholog of human Nucleoporin, NUP98) or RAN-
2 (Ran GTPase activating protein homolog), two conserved
components of the NPC pathway, the movements of N2 animals
were more severely affected than those of EAB242 animals after
treatment with RNAi for 72 h from the L4 stage, as shown in
Figure 3B. Knocking down NPP-10 reduced thrashes/20 seconds
from 36.3 to 10.4 in N2s and from 35.1 to 19.8 in EAB242s
(%Changes: 71.3% vs. 43.6%). Similarly, RAN-2 RNAi lowered
the thrashes to 9.7 in N2s and 17.1 in EAB242s (%Changes:
73.3% vs. 51.3%). Meanwhile, both strains treated with L4440
control RNAi showed a similar number of thrashes (36.3 and
35.1 of N2 and EAB242, respectively). We also tried other NPT
components, such as NPP-5/NUP107 andNPP-6/NUP160 RNAi,
but both N2s and EAB242s were too sick to perform in further
experiments after 1 day of RNAi exposure. We did not use
EAB135 animals as their significantly impaired movement could
be noticed as early as the L4 stage, as compared to N2 animals,
which would make any results difficult to interpret. Collectively,
we concluded that the NPT pathway is likely to be impaired in
our EAB242 animals, which supports the interpretation that the
impaired heat shock response observed in these animals is due to
G4C2 repeats. We would emphasize that several head neurons
(unidentified) of EAB242 and EAB135 were visible under the
regular dissecting microscope at 22∼25◦C. We monitored both
this neuronal GFP signal and the injection marker, a muscular
Ds-RED fusion, when selecting integrated lines. All of the
integrated lines of Phsp−16::(G4C2)9/29::GFP carried both signals
with a 100% transmission rate. Thus, the possibility that the
transgenes were not integrated into the genomes is quite low. In
summary, those transgenic animals with global expression of the
disease-associated construct displayed a series of repeat-number
dependent phenotypes, among which, movement defects and
compromised life span resemble some of the features of illness
observed in ALS patients.
How might neuronal expression of (G4C2)9/29 play a role
in producing those phenotypes? Most of the above-mentioned
phenotypes were also observed in the pan-neuronal expressional
strains of G4C2 [EAB137: (G4C2)9, EAB136: (G4C2)29], but
abnormalities were relatively less severe compared to those in
the globally expressed versions. Albeit, the promoters had to be
different between those transgene constructs. For example, in the
swimming assay, Day 10 adults of EAB136 had 45.7 thrashes/20
s, which was much improved when compared to 4.5 thrashes of
EAB135 animals (Figure 1D). Almost all the tested phenotypes
of the pan-neuronal transgenic displayed a trend toward G4C2
repeat number dependency with the exception of brood size.
Both EAB136 and EAB137 showed a similar reduction of brood
size, which was comparable to EAB135 animals in the normal
culturing condition. This may be a floor effect induced by the
pan-neuronal transgenes, but further studies would be needed to
validate this possibility.
Collectively, we created a series C. elegans strains carrying
disease-related genomic fragments of C9ORF72, and we
observed a sequence-number-repeat/age-dependent locomotor
phenotype, which might be useful for an unbiased genetic screen.
Screening for Suppressors of Locomotive
Defects of EAB135
We initially studied the EAB136 animals, as the pan-neuronal
expression of the transgene might make it a better targeted model
for human ALS-FTLD. However, in the pilot experiments we
failed to distinguish EAB136s and N2s at Days 2–5, by directly
observing their movements under the dissecting microscope, as
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FIGURE 1 | A forward genetic screen identified F57A10.2/VAMP and acp-4/ACP2 as suppressors of C9ORF72 pathology in C. elegans. Generally
(G4C2)29 or Phsp animals produced more severe deficit phenotypes than (G4C2)9 or Punc119, except for the brood size assay. EAB164 animals carrying both
mutations of F57A10.2/VAMP and acp-4/ACP2 had the most suppression of all tested phenotypes. Student t-tests were performed to generate P-values. (A)
Transgenes and transgenic C. elegans lines. (B) Animals expressing C9ORF72 disease-related fragments had delayed developmental phenotypes and suppressors
from the screen partially relieved the defect. N2 (wide type), EAB141, EAB144, EAB137, EAB136, EAB242, and EAB135, and suppressors, EAB164, EAB165, and
(Continued)
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 November 2016 | Volume 9 | Article 113
Wang et al. Suppressors of an ALS Phenotype
FIGURE 1 | Continued
EAB167 were staged for 4 days from about 50 eggs/strain at room temperature. At least three experiments were performed in each case, and a typical experimental
result is shown. For the Phsp animals, EAB135 had the highest lethality on Day 4, compared to strain EAB 242, and both had higher lethality than EAB141 and N2
animals. The lethality was partially relieved in EAB164, EAB165, and EAB167. A similar trend was seen in Punc119animals. (C) Transgenic animals displayed reduced
brood sizes. EAB135, EAB136, and EAB137 animals had similar degrees of reduced brood sizes compared to N2, EAB141, and EAB144 animals. For example,
EAB135 and EAB136 strains had 139 and 123 brood sizes, compared to 272 and 279 in EAB141 and EAB144 strains, respectively. At least 15 animals per strain
were scored in a single experiment, and three independent experiments were performed. (D) Transgenic animals showed age-dependent locomotion defects in
swimming assays. Thrashes/20 s were recorded. Statistically significant differences were found between and among strains, as below, Day 1: EAB135 vs. EAB242
(46 vs. 65, P < 0.05); Day 10: both EAB135 and EAB242 vs. EAB141 (5 and 31 vs. 62, P < 0.05 and < 0.001, respectively). Three independent experiments were
performed in each case. In each experiment, about 30 animals per strain were scored. (E) Transgenic strain EAB135 had the most severely impaired life span,
followed by EAB136 and EAB242 animals. EAB141, EAB144, and EAB137 had a life span similar to N2 animals. Three experiments were independently performed in
each case. Results of a typical experiment are shown, using 35 animals per strain, in which EAB135 animals had a reduced life span of 17 days, compared to about
26 days for the EAB141 strain.
FIGURE 2 | The (G4C2)29 transgene is toxic. Percent lethality on day 10 of
adulthood at three different temperatures are shown. The wild-type N2 (WT)
strain displayed little or no lethality at any temperature tested. Strain EAB135,
carrying the (G4C2)29 transgene, displayed much greater lethality at 20
◦C or
25◦C than strain EAB242, carrying the (G4C2)9 transgene (both P < 0.01).
the locomotor defect of EAB136 was too subtle. We thus chose
to study EAB135 animals, the global expressional version, for a
genetic suppressor screen based on locomotion. We performed
the screen as described in Materials and Methods.
Overall we identified 27 candidates using Day 1 adulthood
animals. Then we performed 6-9 validations. Only those passing
all the validations were studied further. 24 of the 27 suppressor
strains failed validations at least twice. The remaining three
suppressors passed all 9 validations and were named EAB164,
EAB165 and EAB167. EAB164 is a stronger suppressor, in terms
of movement, developmental measures (Figures 1E,D, 4A) and
life span (data not shown), than the EAB165 and EAB167
strains. For example, at Day 5 of adulthood, N2 animals and
EAB135 animals had 63.3 and 24.4 thrashes/20 s, respectively.
EAB164 behaved similarly to N2 and had 61.3 thrashes/20 s.
The other two suppressors moved slower than N2 and EAB164,
but still faster than EAB135. Their thrashes/20 s were 42.2
(EAB165) and 39.2 (EAB166). Genome-wide next generation
sequencing was performed to identify genetic variants unique
to the three suppressors. Each strain carried at least two
nonsense mutations or canonical splicing site mutations (see
Table 1): EAB164 animals carry mutations of acp-4, ugt-42 and
F57A10.2; EAB165 animals carry mutations of nhr-181 and
F57A10.2; EAB167 animals carry T10E9.2, str-46, F57A10.2,
dnj-25 andmrp-2 mutations. Notably, the same nonsense variant
of F57A10.2 was identified in all three suppressors, but not in
wild type animals or EAB135 animals. That nonsense variant
would probably induce NMD, given it localizes more than 55
nucleotides of the end of the second-to-last exon. Even if it
escaped NMD, the resultant 76 amino acid truncated F57A10.2
protein would likely destroy the conserved human sperm protein
(HSP) domain. Thus, it is probably an F57A10.2 null mutant.
The HSP domain is shared with human VAMPs, including VAPA
and VAPB. Interestingly, two pathogenic mutations within the
HSP domain encoding the sequence of VAPB, P56S, and T46I,
have been identified in ALS8 patients (Nishimura et al., 2005;
Chen et al., 2010). Evidence of disruption of normal VAPB
expression, formation of intracellular aggregates and impairment
of axonal transportation of mitochondria, all suggest that these
two variants exert dominant negative functions in ALS8(Teuling
et al., 2007; Chen et al., 2010; Mórotz et al., 2012). This is
consistent with our results that the “null” of the C. elegans
homolog of the human gene, F57A10.2, reversed the ALS-
related phenotypes. This possibility is further supported by
the observation that reduction of F57A10.2 mRNAs leads to
improved movement when EAB135 animals are exposed to
F58A10.2 RNAi bacteria. For example, N2 animals treated for 5
days with F57A10.2 RNAi bacteria had about 48.7 thrashes/ 20 s,
which was significantly more than the 31.2 thrashes/20 s of those
treated with L4440 control RNAi bacteria (Figure 4B). The other
confirmed nonsense variant is in acp-4 of the EAB164 strain. That
variant may also induce NMD as it is on the fourth last exon
from the 3′ end of the gene. Thus, it is also presumably a null
allele. We obtained the VC40826 strain carrying a known acp-4
null allele (gk833833: nonsenseR290Opal) from CGC. VC40826
animals had very obvious movement defects, a phenotype we
used for out-crossing with N2 animals, for five times, to get the
EAB157 strain. EAB157 still displayed movement defects and we
confirmed gk833833 in EAB157 by PCR-sequencing. We crossed
this strain with EAB135 animals in order to introduce gk833833
into the EAB135 background, and generated strain EAB158 [acp-
4(gk833833); EAB135 (Phsp16::(G4C2)29::GFP)]. Consistent with
the lf hypothesis, EAB158 animals had an improved movement
phenotype compared to both EAB135 and EAB157, based on
their Day 5 data. On Day 3, a substantial difference did not exist
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FIGURE 3 | The nuclearpore transportation (NPT) pathway might be impaired in Phsp−16::(G4C2)9/29::GFP transgenic animals. (A) Heat shock-driven
expression of Phsp−16::GFP transgenes. Animals were cultured at 20
◦C and then exposed to 31◦C heat shock for 1 h (right panels) or to no heat shock (left panels).
GFP was significantly expressed after heat shock in EAB141 animals, but was not much enhanced in EAB242 and EAB135 animals. Transgenic constructs were
co-injected with a Pmyo-3::DsRed2 marker. Scale bars are 100 µm. (B) At the L4 stage, N2 and EAB242 animals were treated with NPP-10/NUP98 RNAi and RAN-2
RNAi for 72 h. NPP-10 RNAi reduced thrashes/20 s from 36.3 to 10.4 in N2s and from 35.1 to 19.8 in EAB242s (%Changes: 71.3% vs. 43.6%). RAN-2 RNAi reduced
the thrashes to 9.7 in N2s and 17.1 in EAB242s (%Changes: 73.3% vs. 51.3%). L4440 control RNAi did not affect thrashes (36.3 and 35.1 of N2 and EAB242,
respectively).
FIGURE 4 | Suppressor genes F57A10.2 and acp-4 may exert their effects on C9ORF72 associated pathology via a loss-of-function mechanism. (A)
EAB164, EAB165, and EAB167 were identified as suppressors of the slow movement phenotype of EAB135. All three suppressors were associated with improved
swimming activity in thrashing assays using Day 1, Day 3, and Day 5 adults, compared to EAB135 animals. Strain EAB164 was the most significantly improved
suppressor strain, showing almost similar movement ability to N2 animals. (B) Downregulation of suppressor gene F57A10.2 in EAB135 animals, by feeding RNAi,
produced improved movement in swimming assays, with swimming resembling activity in strains carrying the potential relative null alleles. Total numbers of 50–98
animals were used in each condition. Three experiments were performed in each case. *P < 0.05, **P < 0.0002, ***P < 0.00001. (C) We constructed EAB158
carrying acp-4 (lf,gk833833) on EAB135 background. EAB158 animals moved significantly better than both EAB135 and EAB157 (gk833833). Total numbers of
75–98 animals were used in each condition. Three experiments were performed at room temperature in each case. **P < 0.0002.
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TABLE 1 | List of C. elegans genes that carry significant mutations in the EAB135 suppressors identified from the screen based on slow movement.
C. elegans
gene/chromosome
Human
ortholog/homolog
Protein and function Position Codon change Transcritional/translational
prediction
EAB164
acp-4/II ACP2, ACPT, ACPP Lysosomal acid phosphatase activity 8434143 CGA>TGA STOP
ugt-42/V UGT3A1,UGT3A2 Transferase activity, transferring hexosyl groups 648416 GT>AT TAA introduced
F57A10.2/V VAPA, VAPB 15766903 TCA>TGA STOP
EAB165
nhr-181/V HNF4G A putative nuclear hormone receptor (NHR) 4097868 AG>AA* Frame shift
F57A10.2/V VAPA, VAPB 15766903 TCA>TGA STOP
EAB167
T10E9.2/I 6543341 TCA>TAA STOP
str-46/V 7 transmembrane GPCR, serpentine receptor
class r (Str)
2899516 TGG>TGA STOP
F57A10.2/V VAPA, VAPB 15766903 TCA>TGA STOP
dnj-25/V auxilin Required for clathrin-mediated endocytosis and for
normal development
20743985 AG>AT* PE deletion, frame might not
shift
mrp-2/X MRP1, MRP2 A predicted multidomain transmembrane protein
that is a member of the ATP-binding cassette
superfamily of transport proteins
569906 TGG>TGA STOP
*Splicing site. ACPT, acid phosphatase, testicular; ACPP, acid phosphatase, prostate; ACP2, acid phosphatase 2, lysosomal; UGT3A1, UDP glycosyltransferase 3 family, polypeptide
A1; UGT3A2, UDP glycosyltransferase 3 family, polypeptide A2; VAPA/B, vesicle-associated membrane protein-associated protein A/B; HNF4G, isoform 2 of hepatocyte nuclear factor
4-gamma; MRP1, multidrug resistance-associated protein 1; Dnj-25 is a potential model for Parkinson’s disease.
(Figure 4C). Meanwhile five other genes harboring nonsense
variants or splicing site mutations were also tested for an lf
mechanism, but RNAi experiments based on EAB135 animals
failed to reveal improvement of movement (data not shown),
which indicates either that those variants are not disease-causal
or that they may not act through an lf mechanism.
DISCUSSION
The genetic interaction between F57A10.2/VAPB and the
disease-related repeat of C9ORF72 suggests that F57A10.2/VAPB
is required in C9ORF72-pathology. C9ORF72 has been
demonstrated to participate functionally in endosomal
trafficking, and it co-localizes with Rab proteins (Farg et al.,
2014). C9ORF72 itself is structurally related to DENN Rab-GEFs
(Levine et al., 2013). Additionally, fly VAPB VAP has been
functionally linked to rab-5 (Sanhueza et al., 2015). Thus, it is
conceivable that lf of F57A10.2/VAPB underlies the toxic effects
of C9ORF72 repeats through a RAB pathway. Caution needs to
be noted that the effects of (G4C2) repeats may be irrelevant to
the normal function of C9ORF72.
The stronger suppression of C9ORF72-phenotypes in EAB149
animals carrying mutations of both F57A10.2 and acp-4
suggests that those two suppressor genes may belong to
different pathways; that their effects may be additive. That
deletion of acp-4/ACP2, which probably encodes lysosomal
acid phosphatase, suppressed the C9ORF72 phenotypes suggests
that over-activated lysosomal activity might be pathogenic in
ALS-FTLD. A number of reports have described elevation
of autophagy/lysosomal activity in various tissues from ALS
models/patients (Baker et al., 2015; Pagliardini et al., 2015).
Reducing autophagy activation by n-butylidenephthalide (n-BP)
improved symptoms in ALS transgenic mice (Hsueh et al.,
2016) and upregulating autophagy function, by rapamycin, an
autophagy enhancer, worsened survival of the ALS transgenic
mice (Zhang et al., 2011). Therefore, down-regulation of the
autophagy-lysosome pathway activity via lysosomal ACPs may
represent a potential therapeutic target. Interestingly, C9ORF72
may rescue defects resulting from impaired lysosomal pathway
activity in cultured cells (Busch et al., 2016). These interactions
tentatively position C9ORF72 as a two-way regulator of the
lysosomal pathway. Again, by way of caution, lf of ACP2 may
result in cerebella degeneration/malformation and even neonatal
death (Mannan et al., 2004), which indicates that a proper,
intermediate, level of ACP2 needs to be achieved. Also, before
this target could be used for therapeutic intervention, it would be
essential to determine exactly what reduction of acp2 in which
specific cell/tissue would be sufficient to produce improvement
(Corbier and Sellier, 2016).
A C9ORF72 lf mechanism has been evidenced in the
pathogenetics of C9ORF72-linked ALS-FTD, as well (O’Rourke
et al., 2016). Our group has developed a C9ORF72/ alfa-1(lf)
model in C. elegans (EAB129: gk498021 of alfa-1). RNA-seq
experiments identified a series of differentially expressed genes
in that alfa-1(lf) animal and N2s (unpublished data). One of the
differentially expressed genes, ZK370.8, is an ortholog of human
TTC1 (tetratricopeptide repeat domain 1). Removal of TTC1
produces abnormal vesicular transport in human cells (Lotz et al.,
2008). TTC1 also forms a complex with HSP90 and Rab-8, and
the latter has been suggested to be activated by C9ORF72 and to
function together with C9ORF72 in mediating autophagy. With
many missing pieces to this puzzle, our C. elegansmodels, both lf
and gf, would no doubt exert more power in the future.
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In summary, we developed a disease associated allelic
C9ORF72 model of ALS/FTLD in C. elegans, then identified
and confirmed two genes that harbor genetic variants
which may rescue the disease gene related phenotypes.
Those genetic modifiers might offer new insight on the
mechanism by which the C9ORF72 mutation produces
ALS/FTLD and suggest a target for potential therapeutic
intervention.
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